The Group operates across five continents through 35 companies, 4 branches, 10 manufacturing facilities, and 9 research and development centers. The company operates three segments: immunodiagnostics (66% of sales), molecular diagnostics (17%), and licensed technologies (14%). Notable brands include LIAISON and Verigene systems, along with xMAP technology.
Cyborg Score Rationale
DiaSorin commands a solid market position in in vitro diagnostics with diversified revenue streams across established segments and recent product launches. The company demonstrates strong operational execution with growing margins and global manufacturing footprint. However, the business remains subject to seasonal flu demand variations and post-pandemic normalization headwinds.
Top Insights
Recession-resistant recurring revenue model through dual-channel approach (equipment + consumables) ensures predictable cash generation
Post-COVID normalization impacting core revenue growth—COVID tests declined from 8% to 2% of sales between 2022-2024
Strong gross margins (EBITDA ~35-36%) and disciplined capital allocation support dividend sustainability and strategic M&A
Luminex acquisition (2021) expanded into Life Science/xMAP platform, diversifying beyond traditional IVD and adding higher-margin reagent sales
Named Competitors
Bio-Rad Laboratories — Clinical diagnostics and life science research products
QuidelOrtho — Point-of-care and laboratory diagnostics
Revvity — Diagnostics and life sciences solutions
BioMérieux — In vitro diagnostics for infectious diseases
Randox — Clinical diagnostics and quality assurance
Recent Developments
(February 2026) Stock price at €88.73 with market cap of €4.68B, reflecting valuation pressures from macro headwinds
(2025) H1 revenue of €619M (up 5% YoY) with core business excluding COVID growing 8%, indicating underlying strength
(2024) 3% annual revenue growth reported amid milder flu season demand; COVID contribution down to 2% of total sales
(2025) FDA clearance for LIAISON PLEX® Respiratory Flex Assay testing 19 respiratory pathogens with customizable result options
Open the full interactive DiaSorin S.p.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.